by Scott Larrivee | Jun 26, 2025 | Blog
Nusano’s CEO, Chris Lowe, recently spoke to Ravi Kumar for the Connor Group’s Breakthrough Work podcast. The discussion covered: How Chris went from being CFO to leading Nusano as their CEO How Nusano technology is changing pharma, energy, and other...
by Scott Larrivee | Jun 19, 2025 | News
Alpha-emitting radioisotope expected to play an essential role in next-generation targeted cancer therapies DURHAM, N.C. and WEST VALLEY CITY, Utah – June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a...
by Scott Larrivee | Jun 17, 2025 | News
Agreement provides Ratio access to Nusano-produced radioisotopes for oncology diagnostics and therapeutics Accelerates Ratio’s clinical pipeline with copper-64 for PET imaging and lutetium-177 and actinium-225 for targeted therapy Bolsters both companies’...
by Scott Larrivee | Jun 11, 2025 | News, Utah
Reservations available now, commercial production deliveries begin Q1 2027 Proprietary process with reduced environmental impacts Efficient domestic supply chain needed to support projected growth in energy demand from increased electrification and energy-intensive...
by Scott Larrivee | Jun 10, 2025 | News
Domestic stable isotope program key to stabilizing supply chains, enabling innovation WEST VALLEY CITY, Utah – June 10, 2025 – Nusano today announced it has successfully enriched gadolinium-160 (Gd-160) to 99.2% purity, a significant milestone demonstrating the...
